Non-small cell lung cancer stage IV
RecruitingStudy of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer
Study of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in patients with previously treated stage IV squamous non-small cell lung cancer
- Disease:Non-small cell lung cancer stage IV
- Substances:DocetaxelIfinatamab Deruxtecan+1
Italy- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Merck Sharp & Dohme LLC












